Lyka Labs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Lyka Labs Ltd reported a 10.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 16.4%.
• Its expenses for the quarter were up by 16.1% QoQ and 19.1% YoY.
• The net profit increased 5280.0% QoQ and decreased 497.5% YoY.
• The earnings per share (EPS) of Lyka Labs Ltd declined at 2.13 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lyka Labs Ltd is a company operating in the pharmaceutical industry, known for its focus on developing and manufacturing a range of pharmaceutical products. These typically include active pharmaceutical ingredients (APIs), formulations, and other healthcare solutions. While specific recent developments in the company are not detailed in the data provided, Lyka Labs has historically been involved in expanding its product offerings and enhancing its manufacturing capabilities. As a player in the pharmaceutical sector, the company is subject to industry dynamics such as regulatory changes, market demand for medications, and competitive pressures from both local and international markets.

Revenue

For the fiscal fourth quarter of FY26, Lyka Labs Ltd reported total income of ₹28.64 crores. This represents a decrease of 10.2% compared to the previous quarter (Q3FY26), where the total income was ₹31.89 crores. When comparing year-over-year performance, there is a decline of 16.4% from Q4FY25, where total income was ₹34.25 crores. These figures reflect a downward trend in revenue generation over both the quarter and the year, highlighting changes in the company’s revenue stream during this period.

Profitability

In terms of profitability, Lyka Labs Ltd recorded a significant loss in Q4FY26, with a profit before tax of -₹8.59 crores. This is a substantial increase in the loss compared to Q3FY26, where the profit before tax was -₹0.16 crores. In comparison to Q4FY25, when the profit before tax was ₹3.02 crores, there is a notable year-over-year decline. The profit after tax for Q4FY26 was -₹8.07 crores, which also marked an increase in losses from Q3FY26's -₹0.15 crores and a stark contrast to the profit of ₹2.03 crores in Q4FY25. The earnings per share for Q4FY26 were -₹2.13, showing a decline from both Q3FY26 and Q4FY25, where it was ₹0.00 and ₹0.49, respectively.

Operating Metrics

Lyka Labs Ltd's total expenses for Q4FY26 were ₹37.22 crores, representing a 16.1% increase from Q3FY26, where expenses were ₹32.05 crores. Compared to a year earlier in Q4FY25, when total expenses were ₹31.24 crores, there is a 19.1% increase. This increase in expenses over both the quarterly and yearly periods may reflect operational changes or increased costs. Although specific operating metrics such as the P/E ratio, debt-to-equity ratio, and current ratio are not provided in the data, the available figures highlight trends in the company's financial operations that have impacted overall performance during the reported period.